Paper of the Month - February, 2014

0 rating

Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label Phase II study.

Mariette X, Seror R, Quartuccio L et al.
Gerard Espinosa’s review: Belimumab, an inhibitor of B lymphocyte stimulator (BLyS), has been shown to be effective in patients with systemic lupus erythematosus (SLE) and has been approved in the US and Europe for the treatment of this disease.


READER POLL

Rheum poll 1
Which of the following tests for latent TB infection do you initially perform prior to starting anti-TNF or other immunosuppressive therapies in your patients?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE